Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.13 | 3.77 | 5.43 | 5.30 | 3.10 | 3.36 | 3.78 | 2.24 | 1.51 | 1.98 | 2.77 | 2.54 | 3.41 |
| — | +12.2% | +43.7% | +136.5% | +105.5% | +69.9% | +36.3% | -11.8% | -55.8% | -37.9% | -22.5% | +82.1% | +89.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -73.7% | -21.8% | -35.4% | -39.3% | -30.3% | -23.8% | -20.5% | -14.8% | -17.2% | -19.4% | -17.0% | -15.4% | -16.1% |
| — | +8.2% | -72.3% | -165.3% | -76.6% | -22.7% | -20.8% | +3.8% | -6.6% | -33.5% | -47.8% | -11.9% | -5.7% | |
| ROA | -52.0% | -15.0% | -23.1% | -26.3% | -23.5% | -19.1% | -17.4% | -13.0% | -14.8% | -16.3% | -14.8% | -13.4% | -13.7% |
| — | +21.2% | -33.1% | -102.3% | -59.2% | -17.4% | -17.2% | +3.2% | -8.0% | -29.7% | -47.4% | -10.3% | +2.0% | |
| ROIC | -66.4% | -18.3% | -38.4% | -57.2% | -39.3% | -26.9% | -21.0% | -18.3% | -20.9% | -19.0% | -23.0% | -30.0% | -29.8% |
| — | +32.0% | -82.7% | -212.9% | -88.5% | -41.3% | +8.6% | +39.0% | +29.9% | +11.5% | +20.4% | +87.6% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 167.5% YoY to 14.23x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.40 | 0.40 | 0.20 | 0.39 | 0.08 | 0.07 | 0.06 | 0.05 | 0.04 | 0.07 | 0.06 | 0.06 | 0.09 |
| — | +483.7% | +253.4% | +703.0% | +77.9% | -6.8% | -10.5% | -12.3% | -49.6% | -4.8% | -8.6% | -36.8% | +364.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.23 | 14.23 | 6.38 | 4.19 | 5.13 | 5.32 | 6.44 | 9.25 | 12.05 | 7.09 | 8.24 | 12.99 | 10.71 |
| — | +167.5% | -0.9% | -54.7% | -57.4% | -25.0% | -21.8% | -28.8% | +12.4% | -28.1% | -34.6% | +8.6% | -1.6% | |
| Quick Ratio | 14.23 | 14.23 | 6.38 | 4.19 | 5.13 | 5.32 | 6.44 | 9.25 | 12.05 | 7.09 | 8.24 | 12.99 | 10.71 |
| — | +167.5% | -0.9% | -54.7% | -57.4% | -25.0% | -21.8% | -28.8% | +12.4% | -28.1% | -34.6% | +8.6% | -1.6% | |
| Interest Coverage | -108.87 | -77.19 | -57.13 | -240.71 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCogent Biosciences, Inc.'s current P/E is -15.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cogent Biosciences, Inc.'s business trajectory between earnings reports.